• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms.

作者信息

Sperling Adam S

机构信息

Division of Hematology, Brigham and Women's Hospital, Boston, MA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

出版信息

Blood Adv. 2024 Nov 12;8(21):5527-5528. doi: 10.1182/bloodadvances.2024014308.

DOI:10.1182/bloodadvances.2024014308
PMID:39446348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11544301/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5e9/11544301/1e08ad11c921/BLOODA_ADV-2024-014308-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5e9/11544301/1e08ad11c921/BLOODA_ADV-2024-014308-C-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5e9/11544301/1e08ad11c921/BLOODA_ADV-2024-014308-C-gr1.jpg

相似文献

1
Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms.BCMA嵌合抗原受体T细胞疗法中的血细胞减少：揭示炎症机制
Blood Adv. 2024 Nov 12;8(21):5527-5528. doi: 10.1182/bloodadvances.2024014308.
2
Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows.抗BCMA嵌合抗原受体T细胞疗法后持续血细胞减少与治疗后骨髓造血活性降低有关。
Am J Clin Pathol. 2024 Jul 20. doi: 10.1093/ajcp/aqae083.
3
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.在复发/难治性多发性骨髓瘤中，靶向BCMA的嵌合抗原受体T细胞（CAR T细胞）疗法后T细胞亚群的变化、既往血细胞减少症和高铁蛋白血症与血细胞减少症相关：一项前瞻性综合生物标志物研究的结果
Br J Haematol. 2024 Sep;205(3):999-1010. doi: 10.1111/bjh.19515. Epub 2024 May 8.
4
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤老年患者中的安全性和疗效。
Transplant Cell Ther. 2023 Jun;29(6):350-355. doi: 10.1016/j.jtct.2023.03.012. Epub 2023 Mar 17.
5
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
6
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.CAR-HEMATOTOX 评分作为接受 BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤患者毒性和反应的预后模型。
J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.
7
Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.BCMA 靶向 CAR T 细胞治疗后造血恢复延迟时使用 CD34+ 干细胞增强的疗效和安全性。
Transplant Cell Ther. 2023 Sep;29(9):567-571. doi: 10.1016/j.jtct.2023.05.012. Epub 2023 May 22.
8
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.通过单细胞测序鉴定复发/难治性多发性骨髓瘤中BCMA嵌合抗原受体T细胞（CAR-T）疗法复发的潜在耐药机制和治疗靶点。
Exp Hematol Oncol. 2023 May 8;12(1):44. doi: 10.1186/s40164-023-00402-5.
9
[Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].[两例在鼠源BCMA CAR-T细胞治疗后进展的难治性多发性骨髓瘤患者的人源化BCMA CAR-T细胞挽救治疗]
Zhonghua Xue Ye Xue Za Zhi. 2021 Jun 14;42(6):502-507. doi: 10.3760/cma.j.issn.0253-2727.2021.06.010.
10
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.APRIL 和基于抗体片段的骨髓瘤 CAR T 细胞均可通过 trogocytosis 和内化诱导 BCMA 下调。
J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005091.

本文引用的文献

1
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.促进多发性骨髓瘤患者在接受 BCMA CAR-T 治疗后长期细胞减少症的分子机制。
Blood Adv. 2024 Nov 12;8(21):5479-5492. doi: 10.1182/bloodadvances.2023012522.
2
Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.CD19 CAR T 细胞治疗后细胞减少症持续时间长与克隆性扩增 IFNγ 表达 CD8 T 细胞骨髓浸润有关。
Cell Rep Med. 2023 Aug 15;4(8):101158. doi: 10.1016/j.xcrm.2023.101158.
3
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
CAR-HEMATOTOX 评分作为接受 BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤患者毒性和反应的预后模型。
J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.
4
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
5
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.免疫效应细胞相关性噬血细胞性淋巴组织细胞增生症样综合征。
Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.
6
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
7
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.克隆性造血与 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤时严重神经毒性风险增加相关。
Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177.
8
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗患者的克隆性造血。
Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554.
9
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.嵌合抗原受体 T 细胞相关血液学毒性：复发/难治性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞相关血液学毒性的模型。
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543.
10
Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection.炎症作为疾病、衰老和克隆选择中造血干细胞功能的调节剂。
J Exp Med. 2021 Jul 5;218(7). doi: 10.1084/jem.20201541. Epub 2021 Jun 15.